




PHARMACEUTICAL 2023

Eton Pharmaceuticals Inc.
Rank 235 of 446





RealRate

PHARMACEUTICAL 2023

Eton Pharmaceuticals Inc.
Rank 235 of 446



The relative strengths and weaknesses of Eton Pharmaceuticals Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Eton Pharmaceuticals Inc. compared to the market average is the variable Other Revenues, increasing the Economic Capital Ratio by 85% points. The greatest weakness of Eton Pharmaceuticals Inc. is the variable Assets, Current, reducing the Economic Capital Ratio by 55% points.

The company's Economic Capital Ratio, given in the ranking table, is 73%, being 30% points above the market average of 43%.

Input Variable	Value in 1000 USD
Assets, Current	20,004
Cost of Goods Sold	6,933
Intangible Assets	4,754
Liabilities, Current	6,461
Liabilities, Non-Current	107
Other Assets	200
Other Compr. Net Income	0
Other Expenses	0
Other Liabilities	5,384
Other Net Income	-761
Other Revenues	21,251
Property and Equipment	72
Research and Development	3,996
Selling, General and Administrative Expense	18,582

Output Variable	Value in 1000 USD
Assets	25,030
Liabilities	11,952
Expenses	29,511
Revenues	21,251
Stockholders Equity	13,078
Net Income	-9,021
Comprehensive Net Income	-9,021
Economic Capital Ratio	73%